
Borregaard's core profit slipped to NOK 515 million despite record specialty cellulose output. Adjusted EPS of NOK 2.35 strips out a NOK 337 million Alginor impairment and ground-work charges. The BioSolutions unit lagged on energy costs.
Borregaard ASA logged a second-quarter core profit that slipped slightly from a year earlier, though specialty cellulose deliveries hit a record and fine chemicals bounced back. The Norwegian bio-refiner's EBITDA, defined as operating profit before depreciation, amortisation and other items, came in at NOK 515 million compared with NOK 522 million in the same period of 2025. Revenue rose to NOK 2,114 million from NOK 2,045 million.
The result masked divergent performance across the company's three units. BioMaterials posted a gain on high deliveries of specialty cellulose, a segment that underpins Borregaard's positioning in pharmaceutical and industrial applications. Fine Chemicals also improved on higher shipments and a shift toward more profitable products. BioSolutions was the laggard: higher sales volumes were eaten up by rising energy and energy-related costs, negative currency moves, and a weaker product mix.
CEO Tom Erik Foss-Jacobsen called it "a strong result in a challenging business environment" and pointed to the company's diversified portfolio and broad customer base as the stabilising factor.
Wood costs fell roughly 15% year on year, a bright spot in the cost picture. The offset was the Middle East conflict, which pushed up expenses for energy, logistics and chemicals. The net bill from raw materials, energy and logistics came in about NOK 40 million higher than in the second quarter of 2025.
Borregaard is pushing a cost-cutting programme targeting annual savings of NOK 150 million. The savings phase in gradually with full effect set for 2028. The quarter also included a NOK 30 million charge for ground stabilisation work at its Sarpsborg site and a NOK 337 million impairment of its investment in Alginor ASA, booked through financial items.
Those one-offs dragged headline profit into the red. Pretax profit was NOK -45 million versus NOK 326 million a year earlier. Earnings per share came in at NOK -1.27, down from NOK 2.56. Stripping out the stabilisation and impairment charges, adjusted earnings per share were NOK 2.35.
The stock opened little changed on the Oslo exchange. The adjusted EPS figure, which strips out the impairment and ground-work charges, will draw the most attention from investors who track the underlying operating trajectory. The BioSolutions margin compression is the metric to watch next quarter: energy costs and currency headwinds both tend to be persistent, not one-off.
Prepared with AlphaScala editorial tooling from the source reporting linked above. Indexable analysis may include a cited Alpha Score value. Publishing checks screen each story before release. Educational coverage, not personalized advice.